Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy

Rheumatology International

Volumn 32, Issue 8, 2012, Pages 2523-2527

  Kwon, Seong Ryul ^a   Lim, Mie Jin ^a   Suh, Chang Hee ^b   Park, Shin Goo ^a   Hong, Yeon Sik ^c   Yoon, Bo Young ^d   Kim, Hyoun Ah ^b   Choi, Hyo Jin ^e   Won, Park ^a  

^a Inha University Hospital   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Bupyeong gu   (South Korea)

^d Inje University   (South Korea)

^e Gachon University College of Medicine   (South Korea)

Author keywords

Ankylosing spondylitis; BASDAI; CTX 1; Dickkopf 1; Osteocalcin; Osteoprotegerin; TNF blocker

Indexed keywords

ADALIMUMAB; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; ETANERCEPT; INFLIXIMAB; OSTEOCALCIN; OSTEOPROTEGERIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; OSTEOPROTEGERIN; PEPTIDES; RECEPTORS, TUMOR NECROSIS FACTOR; REPUBLIC OF KOREA; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866250472     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1981-0     Document Type: Article

References (25)

1. Braun J, Brandt J, Listing J et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthr Rheum 48:2224-2233
2. Davis JC, van der Heijde D et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis from 96 weeks. Ann Rheum Dis 64:1557-1562
3. van der Heijde D, Kivitz A, Schiff MH, for the ATLAS Study Group et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthr Rheum 54:2136-2146
4. Davis JC, van der Heijde D, Dougados M, Woolley JM (2005) Reduction in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthr Rheum 53:494-501
5. van der Heijde D, Landewé R, Einstein S et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthr Rheum 58:1324-1331
6. van der Heijde D, Landewé R, Baraliakos X et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthr Rheum 58:3063-3070
7. van der Heijde D (2007) Clinical features of ankylosing spondylitis. In: Klippel JH, Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic diseases, 13th edn. Springer, New York, pp 194-196
8. Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156-163
9. Miller JR (2002) The Wnts. Genome Biol 3:3001.1-3001.15
10. Mao B, Wu W, Davidson G et al (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664-667
11. Holmen SL, Giambernardi TA, Zylstra CR et al (2004) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19:2033-2040
12. Glinka A, Wu W, Delius H, Monaqhan AP, Blumenstock C, Niehrs C (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391:357-362
13. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA (2001) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6. Nat Cell Biol 3:683-686
14. Morvan F, Boulukos K, Clément-Lacroix P et al (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934-945
15. Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494
16. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthr Rheum 27:361-368
17. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286-2291
18. Glass DA II, Bialek P, Ahn JD et al (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764
19. Uderhardt S, Diarra D, Katzenbeisser J et al (2009) Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592-597
20. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumor necrosis factor alpha. Ann Rheum Dis 62:347-349
21. Briot K, Roux C, Gossec L et al (2008) Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. J Rheumatol 35:310-314
22. Visvanathan S, van der Heijde D, Deodhar A et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175-182
23. Schett G, Landewé R, van der Heijde D (2007) TNF blockers and structural remodeling in ankylosing spondylitis - what is reality and what is fiction? Ann Rheum Dis 66:709-711
24. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2 m: an animal model of HLA-B27-associated human disorders. Cell 63:1099-1112
25. Glant TT, Mikecz K, Arzoumanian A, Poole AR (1987) Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthr Rheum 30:201-212